MedTrace Logo

A Study on Multimodal Prognostic Scoring of Advanced PDAC.

NCT07373691 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-01-28

No results posted yet for this study

Summary

The aim of this study is to construct unimodal and multimodal prediction models for overall survival (OS), progression free survival (PFS), and treatment response (complete response+partial response) of advanced first-line chemotherapy based on the imaging, pathological, and genomic characteristics of patients, and evaluate their predictive efficacy.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Qing Xia · RenJi Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-02
Primary Completion
2026-03-01
Completion
2027-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07373691 on ClinicalTrials.gov